Business Segments · Acquired in-process research and development expenses
Business Segments — Acquired in-process research and development expenses
Vertex Pharmaceuticals Business Segments — Acquired in-process research and development expenses decreased by 99.1% to $500K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 97.5%, from $19.8M to $500K. Over 3 years (FY 2022 to FY 2025), Business Segments — Acquired in-process research and development expenses shows an upward trend with a 4.8% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toAcquired in-process research and development
How to read this metric
High values indicate aggressive external growth and pipeline expansion through M&A or licensing.
Detailed definition
One-time costs related to the acquisition of research and development projects from other companies or through licensing...
Peer comparison
Common in biotech; peers often report this as 'In-Process R&D' (IPR&D) charges.
Metric ID:
vrtx_segment_pharmaceuticals_acquired_in_process_research_and_development_expensesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.88M | $28.88M | $28.88M | $28.88M | $131.78M | $131.78M | $131.78M | $131.78M | $76.8M | $4.45B | $15M | $87.5M | $19.8M | $2.2M | $54.5M | $56.5M | $500K |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +356.4% | +0.0% | +0.0% | +0.0% | -41.7% | >999% | -99.7% | +483.3% | -77.4% | -88.9% | >999% | +3.7% | -99.1% |
| YoY Change | — | — | — | — | +356.4% | +356.4% | +356.4% | +356.4% | -41.7% | >999% | -88.6% | -33.6% | -74.2% | -100.0% | +263.3% | -35.4% | -97.5% |
Range$500K – $4.45B
CAGR-63.7%
Avg YoY Growth+345.7%
Median YoY Growth-33.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses?
- Vertex Pharmaceuticals (VRTX) reported business segments — acquired in-process research and development expenses of $500K in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses changed year-over-year?
- Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses decreased by 97.5% year-over-year, from $19.8M to $500K.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses has grown at a 4.8% compound annual growth rate (CAGR), from $115.5M to $133M.
- What does business segments — acquired in-process research and development expenses mean?
- Costs paid to acquire external research projects or drug candidates from other companies.